Specify a stock or a cryptocurrency in the search bar to get a summary
GlaxoSmithKline PLC ADR
GLAXFGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Address: 980 Great West Road, Brentford, United Kingdom, TW8 9GS
Analytics
WallStreet Target Price
46.07 USDP/E ratio
14.2837Dividend Yield
3.71 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GLAXF
Dividend Analytics GLAXF
Dividend growth over 5 years
-16 %Continuous growth
–Payout Ratio 5 years average
68 %Dividend History GLAXF
Stock Valuation GLAXF
Financials GLAXF
Results | 2019 | Dynamics |